0ACH.LSE MedinCell
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0ACH.LSE undervalued?
Graham numberThe Graham number of MedinCell cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MedinCell fundamental analysis
No fundamental analysis for MedinCell yet.
MedinCell stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MedinCell
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, whi…
Full company profileFinancial statements of MedinCell are not available yet.
MedinCell dividends
MedinCell has not paid dividends in the last 4 fiscal years.
Who owns MedinCell
- Insiders 33.97%
- Institutions 32.20%
- Public & others 33.83%
- Free float 32.8M
MedinCell company profile
- Company name
- MedinCell
- Ticker
- 0ACH.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 141
- Fiscal year end
- March
- Address
- 3, rue des Frères Lumière, Jacou, France, 34830
- Phone
- 33 4 67 02 13 67
- Website
- medincell.com
About MedinCell
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
MedinCell management
10- Mr. Christophe DouatCEO & Director · born 1966
- Mr. Stephane PosticChief Financial Officer
- Mr. Philippe MoyenChief Operating Officer
- Ms. Julie AlimiGeneral Counsel & Chief Corporate Development Officer
- Mr. David HeuzeHead of Corporate & Financial Communications and ESG
- Mr. Franck PouzacheChief People Officer
- Mr. Adolfo Lopez-NoriegaHead of Research & Development
- Mr. Sebastien EnaultSenior VP & Chief Business Officer
- Ms. Quiterie De BeauregardHead of Global Health Development
- Dr. Grace Kim Ph.D.Chief Strategy Officer of U.S. Finance